Nezam El-Tayebat 事实核查对“نظام الطيبات”饮食体系的科学评估
选择国家
选择语言: 简体中文

基本正确 有充分科学证据支持 证据确定性: 高 初步 C-INS-04

针对2型糖尿病的大型试验表明，把血糖强化降低到接近正常的糖化血红蛋白（HbA1c）水平可能有害：ACCORD试验因强化治疗使全因死亡率升高22%而被提前终止，而严重低血糖与死亡率约增加一倍相关。

简而言之: 该说法基本正确。ACCORD发现，在高风险2型糖尿病患者中，非常强化的降糖治疗使死亡率升高22%，而且心血管死亡的增加在9年时仍然存在；但总死亡率后来变得没有差异，低血糖也不能解释死亡的增加，而适度的血糖控制仍然是有益的。
结论: 正确：过于激进、接近正常值的控制目标可能伤害高风险的2型糖尿病患者；这支持采用适度、个体化的目标，而不是放弃治疗。
  1. 原始表述
  2. 科学评估
  3. 科学证据详解
  4. 通俗解释
  5. 与该说法相关的研究
  6. 地区背景
  7. 在我的国家适用什么？
  8. 参考文献

原始表述

التجارب الكبرى مثل ACCORD أوقفت العلاج المكثف مبكرًا بعد أن رفع الوفيات 22%، وأظهر تحليل Bonds أن نقص السكر الحاد المصحوب بأعراض ضاعف الوفيات في ذراعَي الدراسة.

按来源为原话. 译文由本项目提供；以阿拉伯语原文为准。

译文

针对2型糖尿病的大型试验表明，把血糖强化降低到接近正常的糖化血红蛋白（HbA1c）水平可能有害：ACCORD试验因强化治疗使全因死亡率升高22%而被提前终止，而严重低血糖与死亡率约增加一倍相关。

出处

来源状态
档案网站编辑
归属
Archive editors (not Elawady)
出处
https://eltayebat.com/rule/insulin-injections/
归属的不确定性
Editorial narrative and study selection written by the archive operators.
所声称的机制

Over-intensification causes hypoglycaemia and other harms.

所声称的健康影响

Higher mortality, severe hypoglycaemia, weight gain

涉及人群

High-risk, long-standing type 2 diabetes

Elawady 设定的地域限制

none found

来源版本存在差异

来源状态
档案网站编辑
归属
Archive editors (not Elawady)
出处
https://eltayebat.com/rule/oral-diabetes-drugs/
归属的不确定性
Editorial narrative and study selection written by the archive operators.

科学评估

基本正确 – 核心内容正确，但有局限或细微不准确之处。

证据确定性: 高 – 进一步研究极不可能改变该评估。

1. 说法是什么？

Intensive glucose lowering in type 2 diabetes increased mortality (ACCORD) and severe hypoglycaemia is linked to death.

2. 哪些内容可证实是正确的？

ACCORD: 10,251 patients, target HbA1c <6.0%: 257 vs 203 deaths, HR 1.22 (95% CI 1.01-1.46); the intensive arm was stopped after 3.5 years; no significant reduction of the primary cardiovascular outcome (HR 0.90) (A-INS-01). Full text reports death from cardiovascular causes HR 1.35 (1.04-1.76), so the archive's 35% figure is correct. VADT found no benefit on major cardiovascular events or death (HR 1.07) and more adverse events, mainly hypoglycaemia (A-INS-03). Severe hypoglycaemia was associated with higher mortality in ACCORD (adjusted HR 1.41 intensive, 2.30 standard arm) (A-INS-14) and with macrovascular events (HR 2.88) and death (HR 2.69) in ADVANCE (A-INS-15). In critically ill patients, tight glucose control (4.5-6.0 mmol/L) increased 90-day mortality (A-INS-02). ADA 2026 states that clinicians 'should not aggressively attempt to achieve near-normal A1C levels' where this cannot be done safely (I-INS-10).

3. 哪些内容是错误或夸大的？

The archive's Arabic headline attributes the ACCORD harm to 'high insulin doses'; ACCORD tested a treatment strategy using many drugs (in the intensive arm 94.7% metformin, 91.7% thiazolidinedione, 86.6% secretagogue and 77.3% any insulin, per full text) and could not attribute the excess mortality to any single drug. Bonds et al. explicitly concluded that hypoglycaemia did not appear to account for the mortality difference between arms (A-INS-14). ADVANCE (target HbA1c <=6.5%) found a 10% reduction in combined major macro- and microvascular events, mainly nephropathy, and no increase in death (HR 0.93) (I-INS-01). UKPDS showed microvascular benefit (A-INS-16) and long-term reductions of myocardial infarction and death (I-INS-02); in type 1 diabetes intensive insulin therapy reduced retinopathy by 76% (I-INS-03). The archive's statement that severe hypoglycaemia doubled mortality 'in both arms' is correct only for the standard arm (adjusted HR 2.30); in the intensive arm the adjusted HR was 1.41 (A-INS-14).

4. 哪些内容仍不明确？

The exact mechanism of excess death in ACCORD remains unexplained. In 9-year follow-up (ACCORDION) the excess of cardiovascular death persisted but was smaller (HR 1.20, 1.03-1.39), while all-cause mortality became neutral (I-INS-123).

5. 哪些研究支持该说法？

A-INS-01, A-INS-02, A-INS-03, A-INS-14, A-INS-15, I-INS-10.

6. 哪些研究与该说法相矛盾？

I-INS-01, I-INS-02, I-INS-03, A-INS-16 (benefits of good, non-extreme control).

7. 对德国和欧洲而言情况如何？

European (EASD) and German (DDG) guidance follow the same evidence base as the ADA/EASD consensus: individualised HbA1c targets, insulin as mandatory therapy in type 1 diabetes, and SGLT2 inhibitors/GLP-1 receptor agonists for people with cardiovascular or kidney disease. No country-specific difference changes the assessment.

8. 关于埃及的已知情况是什么？

Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.

9. 合理的实际结论是什么？

该档案网站的这一部分是准确的，与当前指南一致：糖化血红蛋白（HbA1c）目标应个体化（通常<7%），对于身体虚弱者或老年人要求可适当放宽，治疗应避免低血糖。但这并不支持“降低高血糖普遍有害”的结论。

评估详情

证据确定性的依据

Directly reported RCT results (ACCORD abstract; cardiovascular death HR 1.35 confirmed in full text). Consistent with VADT, ADVANCE and current guidelines. Downgraded from TRUE because the archive omits that ADVANCE showed microvascular benefit, that hypoglycaemia did not explain the ACCORD mortality excess, and that the harm concerned a near-normal target in high-risk patients, not glucose lowering in general.

来源质量

Archive editorial correctly quoting RCTs.

地区可推广性

Trials were multinational (US/Canada, ADVANCE incl. Europe/Asia); transferable.

个体例外情况

Younger people early in the disease without cardiovascular disease may benefit from lower targets if achieved safely (ADA 2026, I-INS-10).

说法的地域范围
普遍性（生物学/医学）
最近审核
2026年10月26日 初步

科学证据详解

有充分科学证据支持 – 该说法与一致的高质量证据相符。

研究问题: In type 2 diabetes, does intensive glucose lowering towards normal HbA1c increase mortality, and is severe hypoglycaemia associated with higher mortality?

研究问题详解 (PICO)
人群
High-risk adults with long-standing type 2 diabetes
干预或暴露
Intensive glycaemic control (HbA1c <6.0-6.5%)
对照
Standard control
地域范围
universal biology
结局指标
  • All-cause and CV mortality
  • Severe hypoglycaemia

研究结果按作者报告呈现。我们的评估见下文。

哪些证据支持该说法？

哪些证据不支持该说法？

总体证据说明了什么？

基于上述研究的编辑评估——其本身并非研究结果。

哪种观点有更好的证据支持？

Near-normal HbA1c targets pursued aggressively in high-risk long-standing T2D can increase CV mortality; moderate, individualised control is beneficial.

为什么有些研究权重更大

Multiple large RCTs and long-term follow-ups.

因果关系是否已确立？ 是，已确立 Randomised evidence.

仍存在的不确定性

Mechanism of ACCORD excess deaths.

合理的结论

Mostly true as reported by the archive.

为什么研究结果看起来互相矛盾？

ACCORD vs ADVANCE/UKPDS differ in population (high-risk long-standing vs newly diagnosed), speed of intensification and targets.

这是否取决于国家？
一般生物学效应
Trials were multinational; findings apply to similar high-risk populations.
饮食习惯
Egyptian and European diets differ, but no dietary pattern replaces insulin in insulin-deficient diabetes.
食品原产地
Not relevant.
污染物
Not relevant.
本国生产条件
Not relevant.
法律规则
Insulin is an essential medicine (WHO list) in Egypt and the EU; prescription rules not relevant to the scientific question.
实际监测数据
Egyptian/Middle Eastern data show severe DKA is common at presentation in children (I-INS-115, I-INS-114); no data on outcomes among Tayebat followers.

足以改变结论的地区差异没有可靠数据支持。

统计复核
  • Absolute risk difference, NNH, CI symmetry – Mortality 5.01% vs 3.96%; ARD 1.05 points (0.25-1.85); NNH about 95 over 3.5 years; HR CI log-symmetric 已重新计算
  • CI symmetry – HR 1.20 (1.03-1.39) symmetric 已重新计算
总体证据的确定性（GRADE，简化版）
主要结局
All-cause mortality with near-normal HbA1c targets in high-risk T2D
起始等级
高（随机试验）
降级理由
  • inconsistency (ADVANCE, VADT neutral)
结果
中

由单名审查者参照 GRADE 方法进行的简化评估；并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据，而非单项研究。

已核查的临床指南和官方声明
  • ADA: 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026 (2026) · 原始文献
    People at risk for DKA should have ketone testing tools and sick-day advice; people on intensive insulin therapy should not stop or hold basal insulin even if not eating; caution with near-normal A1C goals in long-standing T2D using hypoglycaemia-prone drugs (ACCORD).
检索策略

本次审查的文献检索记录（检索式采用原数据库语法）。

数据库日期检索式检索目标命中数纳入数
PubMed2026年10月26日"Nine-Year Effects of 3.7 Years of Intensive Glycemic Control"双向1
Europe PMC2026年10月26日(TITLE:"intensive glucose") AND (TITLE:"meta-analysis") AND (mortality OR "cardiovascular")双向16
PubMed2026年10月26日Hemmingsen B[au] AND intensive glycaemic control AND Cochrane Database Syst Rev[ta]双向3
PubMed2026年10月26日ACCORD AND "9-year" AND mortality AND Diabetes Care[ta]双向2

待解决的问题

The Cochrane review on intensive vs conventional control in T2D (Hemmingsen 2013, PMID 24214280) was withdrawn in 2015 (PMID 26222248) and was not used.

核查深度如何？

13 项相关研究：6 项核查了全文（其中 3 项进行了结构化偏倚风险评估），7 项基于摘要核查，0 项仅核查了文献信息。 尚未进行由两名独立审查者完成的正式评估，也尚未进行独立的人类专家审核。

最近一次科学审核: 2026年10月26日

评定结论的变更历史
  1. 2026年10月25日 · 第 1 阶段 · 初始评估: 基本正确 (高)
  2. 2026年10月26日 · 第 4 阶段（系统证据审查） · 在扩展证据后重新审查；评定结论不变: 基本正确 (高)
    ACCORDION confirms a persistent CV-death excess while total mortality became neutral; this refines but does not change the verdict. Certainty for the claim as a whole (multiple RCTs reporting these figures) remains high even though the mortality outcome alone is inconsistent across trials.
    新来源: I-INS-123

通俗解释

规模非常大的研究检验了：对于糖尿病病程较长、有心脏风险的2型糖尿病患者，把血糖压到几乎正常的水平是否有帮助。在其中一项研究（ACCORD）中，采用非常激进方法的人死亡更多，而血糖过低的发作与死亡相关。其他研究表明，良好但不过度的控制能保护肾脏、眼睛和神经。因此，医生现在会设定个人化的目标，并尽量避免低血糖。

与该说法相关的研究

支持该说法的研究 (8)

  • Very aggressive blood sugar lowering in high-risk type 2 diabetes

    Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC et al.. N Engl J Med 2008 · PMID 18539917 · DOI 10.1056/NEJMoa0802743
    随机对照试验被 Tayebat 档案网站引用已核查全文★ 关键研究

    Pushing HbA1c below 6% increased deaths by about one-fifth and did not reduce heart attacks or strokes significantly.

    该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Does targeting a normal HbA1c (<6.0%) reduce cardiovascular events in type 2 diabetes with high cardiovascular risk?

    研究是如何开展的？

    Multicentre randomised controlled trial (open-label treatment strategies), mean 3.5 years of intensive therapy

    研究了多少人、动物或样本？

    10,251; Type 2 diabetes, mean age 62.2, median HbA1c 8.1%, established CVD or additional risk factors

    实际发现了什么？

    More deaths (HR 1.22) and more severe hypoglycaemia with intensive therapy; primary CV outcome not significantly reduced.

    观察到的效应有多大？

    HR 1.22 (1.01-1.46) all-cause death; HR 0.90 (0.78-1.04) primary outcome

    研究结果对日常生活意味着什么？

    Very strict sugar targets are not good for everyone, especially older people with heart disease.

    该研究有哪些局限？

    Strategy trial: cannot attribute harm to a specific drug; Intensive arm stopped early; High-risk population; not generalisable to early diabetes

    它对 Elawady 的具体说法说明了什么？

    Core evidence that near-normal HbA1c targets can harm high-risk type 2 patients (C-INS-04).

    研究结果是否适用于德国和欧洲？

    Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.

    从该研究中明确不能得出什么结论？

    That insulin specifically caused the deaths, or that lowering high glucose to moderate targets is harmful.

    科学细节 →

  • Very tight blood sugar control in intensive care

    NICE-SUGAR Study Investigators; Finfer S et al.. N Engl J Med 2009 · PMID 19318384 · DOI 10.1056/NEJMoa0810625
    随机对照试验被 Tayebat 档案网站引用已核查摘要

    Aiming for normal blood sugar in ICU patients raised deaths from 24.9% to 27.5%.

    该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Optimal blood glucose target in critically ill ICU patients

    研究是如何开展的？

    International multicentre RCT

    研究了多少人、动物或样本？

    6,104; Adult ICU patients expected to stay >=3 days

    实际发现了什么？

    Higher 90-day mortality and 13-fold more severe hypoglycaemia with intensive control.

    观察到的效应有多大？

    OR 1.14 (1.02-1.28)

    研究结果对日常生活意味着什么？

    In very sick hospital patients, moderate sugar targets are safer.

    该研究有哪些局限？

    ICU population, not ambulatory diabetes; Open-label

    它对 Elawady 的具体说法说明了什么？

    Supports that overly tight targets harm (C-INS-04); both arms received insulin, so it does not support insulin avoidance.

    研究结果是否适用于德国和欧洲？

    Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.

    从该研究中明确不能得出什么结论？

    Anything about insulin therapy in people with diabetes at home.

    科学细节 →

  • Intensive sugar control in veterans with long diabetes

    Duckworth W et al.. N Engl J Med 2009 · PMID 19092145 · DOI 10.1056/NEJMoa0808431
    随机对照试验被 Tayebat 档案网站引用已核查摘要

    Lower sugar did not reduce heart events or deaths, and side effects (mainly hypoglycaemia) were more frequent.

    该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Effect of intensive glucose control on CV events in long-standing type 2 diabetes

    研究是如何开展的？

    Multicentre RCT

    研究了多少人、动物或样本？

    1,791; Military veterans, mean age 60.4, diabetes 11.5 years, 40% prior CV event

    实际发现了什么？

    No significant reduction in CV events or death; more adverse events.

    观察到的效应有多大？

    HR 0.88 (0.74-1.05) primary; HR 1.07 death

    研究结果对日常生活意味着什么？

    In long-standing diabetes, very intensive control brings little benefit and more low-sugar episodes.

    该研究有哪些局限？

    Smaller sample, limited power; Mostly men

    它对 Elawady 的具体说法说明了什么？

    Supports C-INS-04 (no CV benefit, more hypoglycaemia).

    研究结果是否适用于德国和欧洲？

    US veterans; transferable with caution (mostly men).

    从该研究中明确不能得出什么结论？

    That moderate glucose control is useless or that insulin causes death.

    科学细节 →

  • Severe low blood sugar and death in ACCORD

    Bonds DE et al.. BMJ 2010 · PMID 20061358 · DOI 10.1136/bmj.b4909
    队列研究被 Tayebat 档案网站引用全文，含结构化偏倚风险评估★ 关键研究

    People who had severe low-sugar episodes died more often, but this did not explain why the intensive group had more deaths.

    该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Link between severe hypoglycaemia and mortality in ACCORD

    研究是如何开展的？

    Retrospective epidemiological analysis within an RCT (ACCORD)

    研究了多少人、动物或样本？

    10,194; ACCORD participants with hypoglycaemia assessment

    实际发现了什么？

    Deaths were more common after severe low-sugar episodes (adjusted HR 1.41 and 2.30), but only 1 of 451 deaths was definitely caused by low sugar, and it explained only about 5 of 57 extra deaths in the intensive group.

    观察到的效应有多大？

    aHR 1.41 (1.03-1.93) intensive arm

    研究结果对日常生活意味着什么？

    Severe hypoglycaemia is a danger sign to avoid.

    该研究有哪些局限？

    Post-hoc observational analysis; Confounding by frailty

    它对 Elawady 的具体说法说明了什么？

    Supports C-INS-04 (hypoglycaemia is a marker of risk); limits causal interpretation.

    研究结果是否适用于德国和欧洲？

    Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.

    从该研究中明确不能得出什么结论？

    That hypoglycaemia caused the ACCORD excess mortality.

    科学细节 →

  • Severe hypoglycaemia in ADVANCE

    Zoungas S et al.. N Engl J Med 2010 · PMID 20925543 · DOI 10.1056/NEJMoa1003795
    队列研究被 Tayebat 档案网站引用全文，含结构化偏倚风险评估

    Severe low-sugar episodes were followed by more heart events and deaths, probably partly because frail people get them.

    该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Severe hypoglycaemia and vascular events/death

    研究是如何开展的？

    Post-hoc cohort analysis of an RCT (ADVANCE)

    研究了多少人、动物或样本？

    11,140; ADVANCE participants with type 2 diabetes

    实际发现了什么？

    aHR 2.69 death.

    观察到的效应有多大？

    aHR 2.69 (1.97-3.67)

    研究结果对日常生活意味着什么？

    Avoid severe hypoglycaemia.

    该研究有哪些局限？

    Only 231 people had severe hypoglycaemia; links also seen with skin and digestive disease (suggesting frailty); no dose-response; intensive treatment was a sulfonylurea, not insulin; funded by the drug's manufacturer.

    它对 Elawady 的具体说法说明了什么？

    Supports C-INS-04; kernel of C-INS-02.

    研究结果是否适用于德国和欧洲？

    Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.

    从该研究中明确不能得出什么结论？

    Causation.

    科学细节 →

  • Very aggressive blood sugar lowering in high-risk type 2 diabetes

    Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC et al.. N Engl J Med 2008 · PMID 18539917 · DOI 10.1056/NEJMoa0802743
    随机对照试验被 Tayebat 档案网站引用已核查全文★ 关键研究

    Pushing HbA1c below 6% increased deaths by about one-fifth and did not reduce heart attacks or strokes significantly.

    该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Does targeting a normal HbA1c (<6.0%) reduce cardiovascular events in type 2 diabetes with high cardiovascular risk?

    研究是如何开展的？

    Multicentre randomised controlled trial (open-label treatment strategies), mean 3.5 years of intensive therapy

    研究了多少人、动物或样本？

    10,251; Type 2 diabetes, mean age 62.2, median HbA1c 8.1%, established CVD or additional risk factors

    实际发现了什么？

    More deaths (HR 1.22) and more severe hypoglycaemia with intensive therapy; primary CV outcome not significantly reduced.

    观察到的效应有多大？

    HR 1.22 (1.01-1.46) all-cause death; HR 0.90 (0.78-1.04) primary outcome

    研究结果对日常生活意味着什么？

    Very strict sugar targets are not good for everyone, especially older people with heart disease.

    该研究有哪些局限？

    Strategy trial: cannot attribute harm to a specific drug; Intensive arm stopped early; High-risk population; not generalisable to early diabetes

    它对 Elawady 的具体说法说明了什么？

    Core evidence that near-normal HbA1c targets can harm high-risk type 2 patients (C-INS-04).

    研究结果是否适用于德国和欧洲？

    Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.

    从该研究中明确不能得出什么结论？

    That insulin specifically caused the deaths, or that lowering high glucose to moderate targets is harmful.

    科学细节 →

  • Intensive sugar control in veterans with long diabetes

    Duckworth W et al.. N Engl J Med 2009 · PMID 19092145 · DOI 10.1056/NEJMoa0808431
    随机对照试验被 Tayebat 档案网站引用已核查摘要

    Lower sugar did not reduce heart events or deaths, and side effects (mainly hypoglycaemia) were more frequent.

    该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Effect of intensive glucose control on CV events in long-standing type 2 diabetes

    研究是如何开展的？

    Multicentre RCT

    研究了多少人、动物或样本？

    1,791; Military veterans, mean age 60.4, diabetes 11.5 years, 40% prior CV event

    实际发现了什么？

    No significant reduction in CV events or death; more adverse events.

    观察到的效应有多大？

    HR 0.88 (0.74-1.05) primary; HR 1.07 death

    研究结果对日常生活意味着什么？

    In long-standing diabetes, very intensive control brings little benefit and more low-sugar episodes.

    该研究有哪些局限？

    Smaller sample, limited power; Mostly men

    它对 Elawady 的具体说法说明了什么？

    Supports C-INS-04 (no CV benefit, more hypoglycaemia).

    研究结果是否适用于德国和欧洲？

    US veterans; transferable with caution (mostly men).

    从该研究中明确不能得出什么结论？

    That moderate glucose control is useless or that insulin causes death.

    科学细节 →

  • ADA guideline 2026: blood sugar goals and emergencies

    American Diabetes Association Professional Practice Committee for Diabetes* . Diabetes Care 2026 · PMID 41358894 · DOI 10.2337/dc26-S006
    指南 / 立场声明独立交叉核查已核查全文★ 关键研究

    Most adults should aim for HbA1c below 7%, avoid low sugar, and measure ketones when at risk.

    该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Glycaemic goals, hypoglycaemia and hyperglycaemic crises

    研究是如何开展的？

    Clinical practice guideline (ADA Standards of Care 2026, Section 6)

    研究了多少人、动物或样本？

    not applicable; People with diabetes

    实际发现了什么？

    Individual targets; do not stop basal insulin when not eating.

    观察到的效应有多大？

    not applicable

    研究结果对日常生活意味着什么？

    Moderate targets and safety rules.

    该研究有哪些局限？

    US-centred; Partially read

    它对 Elawady 的具体说法说明了什么？

    Supports C-INS-04, C-INS-11; contradicts C-FAST-01, C-FAST-03, C-DIAB-02.

    研究结果是否适用于德国和欧洲？

    Consistent with EASD guidance.

    从该研究中明确不能得出什么结论？

    Not applicable.

    科学细节 →

与该说法相矛盾或限制该说法的研究 (3)

  • ADVANCE: intensive control to HbA1c 6.5%

    ADVANCE Collaborative Group; Patel A et al.. N Engl J Med 2008 · PMID 18539916 · DOI 10.1056/NEJMoa0802987
    随机对照试验独立交叉核查全文，含结构化偏倚风险评估★ 关键研究

    Fewer kidney complications and no extra deaths, but more severe hypoglycaemia.

    该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Effect of intensive glucose control (gliclazide MR-based, HbA1c <=6.5%) on vascular outcomes

    研究是如何开展的？

    Multicentre factorial RCT (ADVANCE glucose arm)

    研究了多少人、动物或样本？

    11,140; Type 2 diabetes with high vascular risk

    实际发现了什么？

    10% fewer combined events; no mortality difference.

    观察到的效应有多大？

    HR 0.90 (0.82-0.98)

    研究结果对日常生活意味着什么？

    Moderately intensive control is safe and protects kidneys.

    该研究有哪些局限？

    Open-label; kidney benefit mainly less protein in urine; underpowered for heart attacks/strokes; funded by the drug's manufacturer (analysis independent).

    它对 Elawady 的具体说法说明了什么？

    Limits C-INS-04 (intensive control is not uniformly harmful); contradicts C-ODD-11.

    研究结果是否适用于德国和欧洲？

    Multinational trial including European sites or directly applicable to EU practice.

    从该研究中明确不能得出什么结论？

    Benefit for heart attacks/stroke.

    科学细节 →

  • UKPDS legacy: 10 years after the trial

    Holman RR et al.. N Engl J Med 2008 · PMID 18784090 · DOI 10.1056/NEJMoa0806470
    随机对照试验独立交叉核查已核查摘要★ 关键研究

    People treated intensively early with sulfonylureas or insulin had 15% fewer heart attacks and 13% fewer deaths years later.

    该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Do UKPDS benefits persist and do macrovascular effects emerge?

    研究是如何开展的？

    Post-trial monitoring of an RCT (UKPDS 80)

    研究了多少人、动物或样本？

    4,209 randomised; 3,277 monitored; Newly diagnosed type 2 diabetes from UKPDS

    实际发现了什么？

    Legacy reductions in MI and death.

    观察到的效应有多大？

    Death -13% (SU/insulin), -27% (metformin)

    研究结果对日常生活意味着什么？

    Early good control pays off for decades.

    该研究有哪些局限？

    Post-trial therapy not controlled; Questionnaire follow-up

    它对 Elawady 的具体说法说明了什么？

    Contradicts C-INS-03, C-INS-05 and C-DIAB-01: early insulin/SU therapy reduced MI and death long-term.

    研究结果是否适用于德国和欧洲？

    UK; directly relevant.

    从该研究中明确不能得出什么结论？

    Effects of extreme targets in late disease.

    科学细节 →

  • DCCT: better insulin treatment in type 1 diabetes

    Diabetes Control and Complications Trial Research Group; Nathan DM et al.. N Engl J Med 1993 · PMID 8366922 · DOI 10.1056/NEJM199309303291401
    随机对照试验独立交叉核查已核查摘要★ 关键研究

    Intensive insulin cut the risk of eye damage by three-quarters and nerve damage by 60%, with more low-sugar episodes.

    该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Does intensive insulin therapy reduce long-term complications in type 1 diabetes?

    研究是如何开展的？

    Multicentre RCT (DCCT)

    研究了多少人、动物或样本？

    1,441; Insulin-dependent (type 1) diabetes

    实际发现了什么？

    Large reductions in all microvascular complications.

    观察到的效应有多大？

    Retinopathy -76%

    研究结果对日常生活意味着什么？

    Insulin protects eyes, kidneys and nerves in type 1 diabetes.

    该研究有哪些局限？

    Open-label; Selected young population

    它对 Elawady 的具体说法说明了什么？

    Contradicts C-INS-07, C-INS-09, C-DIAB-01; shows insulin efficacy and hypoglycaemia cost (C-INS-02 kernel).

    研究结果是否适用于德国和欧洲？

    North American; universally accepted.

    从该研究中明确不能得出什么结论？

    Effects in type 2 diabetes directly.

    科学细节 →

结果不一或不明确的研究 (2)

  • UKPDS: tablets or insulin for new type 2 diabetes

    UKPDS Group. Lancet 1998 · PMID 9742976
    随机对照试验被 Tayebat 档案网站引用已核查摘要★ 关键研究

    Better sugar control with tablets or insulin cut eye/kidney complications by a quarter; insulin caused more weight gain and low-sugar episodes.

    该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Intensive control with sulfonylurea or insulin vs diet on complications

    研究是如何开展的？

    Multicentre RCT (UKPDS 33)

    研究了多少人、动物或样本？

    3,867; Newly diagnosed type 2 diabetes, median age 54

    实际发现了什么？

    Microvascular -25%; more hypoglycaemia and weight gain with insulin.

    观察到的效应有多大？

    RR reduction 25% microvascular

    研究结果对日常生活意味着什么？

    Insulin helps prevent complications but has side effects.

    该研究有哪些局限？

    Open-label; Older drug regimens

    它对 Elawady 的具体说法说明了什么？

    Supports weight/hypoglycaemia (C-INS-01); contradicts C-INS-03, C-INS-05, C-DIAB-01.

    研究结果是否适用于德国和欧洲？

    UK; directly relevant.

    从该研究中明确不能得出什么结论？

    That insulin is harmful overall.

    科学细节 →

  • ACCORD nine years later

    ACCORD Study Group. Diabetes Care 2016 · PMID 26822326 · DOI 10.2337/dc15-2283
    随机对照试验独立交叉核查已核查摘要★ 关键研究

    Very intensive sugar lowering in high-risk type 2 diabetes still showed more cardiovascular deaths after 9 years, but overall deaths were no longer different.

    CV death remained raised (HR 1.20), but all-cause death neutral at 9 years.

    该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Follow ACCORD participants long term.

    研究是如何开展的？

    Post-trial follow-up.

    研究了多少人、动物或样本？

    8,601 people.

    实际发现了什么？

    CV death HR 1.20; all-cause death neutral.

    观察到的效应有多大？

    HR 1.20 (1.03-1.39).

    研究结果对日常生活意味着什么？

    Very aggressive targets are not advisable for high-risk patients.

    该研究有哪些局限？

    Post-trial care varied.

    它对 Elawady 的具体说法说明了什么？

    Supports caution; adds that total mortality became neutral.

    研究结果是否适用于德国和欧洲？

    Applicable.

    从该研究中明确不能得出什么结论？

    Cannot attribute harm to insulin alone.

    科学细节 →

地区背景

德国 / 欧盟

European (EASD) and German (DDG) guidance follow the same evidence base as the ADA/EASD consensus: individualised HbA1c targets, insulin as mandatory therapy in type 1 diabetes, and SGLT2 inhibitors/GLP-1 receptor agonists for people with cardiovascular or kidney disease. No country-specific difference changes the assessment.

埃及

Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.

在我的国家适用什么？

一般科学评估

基本正确 正确：过于激进、接近正常值的控制目标可能伤害高风险的2型糖尿病患者；这支持采用适度、个体化的目标，而不是放弃治疗。

该说法涉及生物学或医学关系。上述科学评估不论在哪个国家都适用；各国食品数据不会改变这一评估。

参考文献

  1. Effects of intensive glucose lowering in type 2 diabetes.. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC et al.. N Engl J Med 2008 · PMID 18539917 · DOI 10.1056/NEJMoa0802743
  2. Intensive versus conventional glucose control in critically ill patients.. NICE-SUGAR Study Investigators; Finfer S et al.. N Engl J Med 2009 · PMID 19318384 · DOI 10.1056/NEJMoa0810625
  3. Glucose control and vascular complications in veterans with type 2 diabetes.. Duckworth W et al.. N Engl J Med 2009 · PMID 19092145 · DOI 10.1056/NEJMoa0808431
  4. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study.. Bonds DE et al.. BMJ 2010 · PMID 20061358 · DOI 10.1136/bmj.b4909
  5. Severe hypoglycemia and risks of vascular events and death.. Zoungas S et al.. N Engl J Med 2010 · PMID 20925543 · DOI 10.1056/NEJMoa1003795
  6. Effects of intensive glucose lowering in type 2 diabetes.. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC et al.. N Engl J Med 2008 · PMID 18539917 · DOI 10.1056/NEJMoa0802743
  7. Glucose control and vascular complications in veterans with type 2 diabetes.. Duckworth W et al.. N Engl J Med 2009 · PMID 19092145 · DOI 10.1056/NEJMoa0808431
  8. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026.. American Diabetes Association Professional Practice Committee for Diabetes* . Diabetes Care 2026 · PMID 41358894 · DOI 10.2337/dc26-S006
  9. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.. ADVANCE Collaborative Group; Patel A et al.. N Engl J Med 2008 · PMID 18539916 · DOI 10.1056/NEJMoa0802987
  10. 10-year follow-up of intensive glucose control in type 2 diabetes.. Holman RR et al.. N Engl J Med 2008 · PMID 18784090 · DOI 10.1056/NEJMoa0806470
  11. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.. Diabetes Control and Complications Trial Research Group; Nathan DM et al.. N Engl J Med 1993 · PMID 8366922 · DOI 10.1056/NEJM199309303291401
  12. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.. UKPDS Group. Lancet 1998 · PMID 9742976
  13. Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes.. ACCORD Study Group. Diabetes Care 2016 · PMID 26822326 · DOI 10.2337/dc15-2283

← 返回概览